AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share

PRESS RELEASEFOLLOWING RELEASE OF FYE2025 RESULTS AND SECURING OF CLINICAL TRIAL INSURANCE POLICY, MAXIM GROUP REITERATES ITS BUY RECOMMENDATION ...
Business Insider

AB Science reports its revenues for the year 2025 and provides an update on its activities

AB SCIENCE PRESENTS ITS ANNUAL FINANCIAL RESULTS AS OF 31 DECEMBER 2025 AND KEY EVENTS FOR THE PERIOD Paris, 13 May 2025, 7pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces its ...

AB Science’s Masitinib MS Trial Update: What Suspended Phase 3 Activity Means for Investors

AB Science (ABSCF) is running a late-stage study of masitinib in progressive multiple sclerosis, a severe form of the disease with limited options. The trial, officially titled “A 96-Week, Prospective ...
Seeking Alpha

Stonegate Capital Partners Initiates Coverage on AB Science S.A. (AB)

Dallas, Texas--(Newsfile Corp. - February 10, 2026) - AB Science S.A. (ENXTPA: AB): Stonegate Capital Partners Initiates Coverage on AB Science S.A. (ENXTPA: AB). AB Science is a late-stage biotech ...